Paper Details

  1. Home
  2. Paper Details

Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial.

Author: LamChing, LeightonMatthew P, MehtaSamir, SpillerRobin C

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study aims to test the effectiveness of mesalazine, a medication used for inflammatory bowel disease, in treating diarrhea-predominant irritable bowel syndrome (IBS). The study will also investigate how mesalazine works, particularly its potential impact on mast cells, which are involved in inflammation.
Paper Details　
Original Abstract of the Article :
Irritable bowel syndrome (IBS) is reported by one in ten of the population accounting for up to 40% of new referrals to gastroenterology outpatients. Patients characteristically have abdominal discomfort and disturbed bowel habit. Diarrhoea-predominant IBS is characterised by frequent loose stools w...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551830/

データ提供：米国国立医学図書館（NLM）

Mesalazine: A Potential Oasis in the Desert of IBS-D

The world of irritable bowel syndrome (IBS) is a complex and often uncomfortable one, with researchers constantly seeking new and effective treatments for this debilitating condition. This study focuses on mesalazine, an anti-inflammatory drug, and its potential role in treating diarrhea-predominant IBS (IBS-D). The authors meticulously outline a study protocol for a randomized controlled trial, highlighting the importance of evaluating mesalazine's efficacy in reducing IBS-D symptoms and investigating its potential mechanisms of action, particularly its impact on mast cell activation.

Mesalazine: A Glimmer of Hope in the Desert of IBS-D

This study offers a promising avenue for exploring new treatment options for IBS-D. By investigating the efficacy and mechanisms of action of mesalazine, researchers aim to provide a more targeted and effective approach to managing this condition. These findings, like a refreshing oasis in the desert of IBS-D, could offer relief for millions of individuals struggling with this debilitating condition.

Finding Relief: Navigating the Desert of IBS-D

This research emphasizes the need for continued exploration of new and innovative treatment options for IBS-D. By understanding the mechanisms behind mesalazine's potential benefits, researchers can develop more targeted and effective therapies, ultimately improving the quality of life for those affected by this condition. Just as a camel relies on its adaptations to navigate the harsh desert environment, we must continue to develop new tools and strategies to combat the challenges of IBS-D.

Dr.Camel's Conclusion

This study represents a journey into the heart of the desert of IBS-D, seeking to uncover new and effective treatments. By exploring the potential of mesalazine, researchers are striving to create a more navigable path through this complex and often uncomfortable condition. It's a reminder that even in the most challenging deserts, there are opportunities for finding relief and improving the lives of those affected.

Date :
  1. Date Completed 2013-07-09
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

23302220

DOI: Digital Object Identifier

PMC3551830

Related Literature

Article Analysis
・Effective treatment of irritable bowel syndrome
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.